Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 26, 2007

Intradigm Selects Agilent as Manufacturing Partner for RNAi Oncology Therapeutic

  • Intradigm chose Agilent Technologies to manufacture the active siRNA component of its RNAi therapeutic. In addition, Intradigm selected ICS-283 as its lead RNAi product candidate.

    Under terms of the agreement, Agilent will support the initiation of clinical development for ICS-283. Intradigm expects to initiate trials in 2008.

    ICS-283 is the only systemic RNAi therapeutic in preclinical development against a clinically validated oncology target (vascular endothelial growth factor or VEGF), according to Intradigm. It is a nanoparticle-based compound comprised of multiple siRNAs that target both VEGF and its receptor.

  • You’re all set! Thank you for subscribing to GEN Highlights.